Chinese pharmaceutical company Shenzhou Yiqiao Information Service has divested its 100% stake in gelatin products manufacturer Qinghai Gelatin and pharmaceutical company Qinghai Mingnuo Capsule.

The company simultaneously sold a 67.03% stake in fish gelatin producer Guangdong Mingyang Gelatin and 100% stake in collagen casing manufacturer LiuzhouCity Hongsheng collagen casings.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

“Chinese bio-medicine products manufacturer Walvax Biotechnology plans to sell its stake in its Shanghai-based pharma-tech unit for CNY100m ($15.36m).”

Chinese bio-medicine products manufacturer Walvax Biotechnology plans to sell its stake in its Shanghai-based pharma-tech unit for CNY100m ($15.36m).

Kangmei Pharmaceutical has agreed to purchase an 80% stake in a pharmaceutical company based in Huizhou, China, for CNY20.8m ($3.18m).

The acquirer company is also based in China and involved in the production and distribution of herbal medicine.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact